ClinicalTrials.gov record
Completed Phase 2 Interventional

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

ClinicalTrials.gov ID: NCT01594983

Public ClinicalTrials.gov record NCT01594983. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Active Comparator, Placebo Controlled, Double-blind Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Study identification

NCT ID
NCT01594983
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
58 participants

Conditions and interventions

Interventions

  • Fenofibrate Drug
  • Fish Oil Drug
  • LCQ908 Drug
  • Placebo of LCQ908 Drug
  • Placebo of fenofibrate Drug
  • Placebo of fish oil Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2012
Primary completion
Jun 30, 2013
Completion
Jun 30, 2013
Last update posted
Dec 16, 2020

2012 – 2013

United States locations

U.S. sites
28
U.S. states
15
U.S. cities
26
Facility City State ZIP Site status
Novartis Investigative Site Muscle Shoals Alabama 35662
Novartis Investigative Site Glendale Arizona 85306
Novartis Investigative Site Encinitas California 92024-1332
Novartis Investigative Site Colorado Springs Colorado 80906
Novartis Investigative Site Brandon Florida 33511
Novartis Investigative Site Miami Florida 33156
Novartis Investigative Site Ocala Florida 34471
Novartis Investigative Site Orange City Florida 32763
Novartis Investigative Site Orlando Florida 32806
Novartis Investigative Site Port Orange Florida 32127
Novartis Investigative Site St. Petersburg Florida 33709
Novartis Investigative Site Louisville Kentucky 40213
Novartis Investigative Site Oxon Hill Maryland 20745
Novartis Investigative Site Butte Montana 59701
Novartis Investigative Site Cary North Carolina 27518
Novartis Investigative Site Salisbury North Carolina 28144
Novartis Investigative Site Lyndhurst Ohio 44124
Novartis Investigative Site Marion Ohio 43302
Novartis Investigative Site Oklahoma City Oklahoma 73103
Novartis Investigative Site Oklahoma City Oklahoma 73112
Novartis Investigative Site Oklahoma City Oklahoma 73135
Novartis Investigative Site Tulsa Oklahoma 74136
Novartis Investigative Site Eugene Oregon 97404
Novartis Investigative Site Lansdale Pennsylvania 19446
Novartis Investigative Site Bristol Tennessee 37620
Novartis Investigative Site Boerne Texas 78006
Novartis Investigative Site Corpus Christi Texas 78404
Novartis Investigative Site Houston Texas 77074

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01594983, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2020 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01594983 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →